Standardized uptake values for breast carcinomas assessed by fluorodeoxyglucose-positron emission tomography correlate with prognostic factors

American Surgeon

Volumn 73, Issue 11, 2007, Pages 1151-1157

  Ikenaga, Naoki ^a,d   Otomo, Naoki ^a   Toyofuku, Atsushi ^a   Ueda, Yuji ^a   Toyoda, Kiyokazu ^a   Hayashi, Tohru ^a   Nishikawa, Kiyoshi ^b   Tanaka, Masao ^c  

^a Miyazaki Prefectural Institute   (Japan)

^b Miyazaki Tsuruta Memorial Clinic   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d UNIVERSITY OF MIYAZAKI HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE; PROGESTERONE RECEPTOR; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CLINICAL ARTICLE; COMPARATIVE STUDY; DIAGNOSTIC VALUE; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MASTECTOMY; METASTASIS; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PROGNOSIS; STANDARD; TUMOR VOLUME; BREAST TUMOR; CANCER STAGING; CARCINOMA; DIFFERENTIAL DIAGNOSIS; FOLLOW UP; METABOLISM; METHODOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES;

EID: 38449119323     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Rigo P, Paulus P, Kaschten BJ, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996;23:1641-74.
2. Weber WA, Avril N, Schwaiger M. Relevance of positron emission tomography (PET) in oncology. Strahlenther Onkol 1999;175:356-73.
3. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: Initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991;179:765-70.
4. Avril N, Rose CA, Schelling M, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: Use and limitations. J Clin Oncol 2000;18:3495-502.
5. Adler LP, Crowe JP, al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluorp-D-glucose PET. Radiology 1993;187:743-50.
6. Schirrmeister H, Kuhn T, Guhlmann A, et al. Fuluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: Comparison with the standard staging procedures. Eur J Nucl Med 2001;28:351-8.
7. Weir L, Worsley D, Bernstein V. The value of FDG positron emission tomography in the management of patients with breast cancer. Breast J 2005;11:204-9.
8. Wahl R, Siegel B, Coleman RE, Gatsonis CG; PET Study Group. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: A report of the staging breast cancer with PET Study Group. J Clin Oncol 2004;22:277-85.
9. Breast Cancer Treatment Guidelines for Patients - Version VIII. September 2006, http://www.nccn.org/patients/patient_gls/_english/_breast/contents.asp. Accessed September 4, 2007.
10. American Joint Committee on Carcinoma. Carcinoma Staging Manual. New York: Lippincott-Raven, 1997.
11. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
12. Avril N, Dose J, Janicke F, et al. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 1996;14:1848-57.
13. Buck A, Schirrmeister H, Kuhn T, et al. FDG uptake in breast carcinoma: Correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 2002;29:1317-23.
14. 18F-FDG PET: Histologic and immunohistochemical tissue analysis. J Nucl Med 2001;42:9-16.
15. Crippa F, Seregni E, Agresti R, et al. Association between F-18 fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast carcinoma: A preliminary observation. Eur J Nucl Med 1998;25:1429-34.
16. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast carcinoma cases. Carcinoma 1989;63:181-7.
17. Bloom HJG, Richardson WW. Histological grading and prognosis in breast carcinoma. Br J Carcinoma 1957;11:359-77.
18. Goldhirsch A, Glick JH, Gelber RD, et al. Panel members. Meeting highlights: International expert consensus on the primary therapy of early breast carcinoma 2005. Ann Oncol 2005;16:1569-83.
19. Fisher B, Redmond C, Fisher ER, Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: Findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 1988;6:1076.
20. McGuire WL, Tandon AK, Allred DC, et al. How to use prognostic factors in axillary node-negative breast carcinoma patients. J Natl Carcinoma Inst 1990;82:1006.
21. Barnard NJ, Hall PA, Lemoine NR, Kadar N. Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables. J Pathol 1987;152:287-95.
22. MacGrogan G, Mauriac L, Durand M, et al. Primary chemotherapy in breast invasive carcinoma: Predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MIB1, pS2 and GST pi. Br J Cancer 1996;74:1458-65.
23. Jansson T, Westlin JE, Ahlstrom H, et al. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: A method for early therapy evaluation? J Clin Oncol 1995;13:1470-7.